journal article·2020-05

Fluorescent zwitterionic Iridium(III) complexes containing sulfonate groups: synthesis, biological activity and tracking in live cells

Yanjing Yang, Lihua Guo, Xingxing Ge, Wenjing Chen, Huanxing Zhou, Teng Zhu, Xin Li, Shujing Tuo, Zhe Liu

Dyes and Pigments· Volume 176
Publisher page

Abstract

Abstract Fluorescent zwitterionic iridium complexes have been rarely reported. In this work, four fluorescent zwitterionic cyclometalated iridium complexes bearing different sulfonated iminopyridine ligands (Ir1–Ir4) were synthesized. The solid-state molecular structure of Ir1 was established by X-ray crystallography. These zwitterionic complexes are very stable in aqueous solution and have a detectable fluorescence. The structure-activity relationship toward cancer cells was observed for these complexes. Further, the fluorescence properties of these zwitterionic complexes make it possible to determine their microscopic mechanism by the cell imaging. It is noteworthy that complex Ir3 can specifically and effectively target lysosomes and induce cell death by damaging lysosomes Further, the energy-dependent pathway was involved in the uptake of Ir3 in cancer cells. In addition, the modes of cell death were also studied through flow cytometry experiments. It seems that Ir3 displayed their biological efficacy by cell-cycle arrest and the induction of cell apoptosis.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Metal complexes synthesis and properties · Organic Light-Emitting Diodes Research · Ferrocene Chemistry and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (61)

Show source-provided references
1. The resurgence of platinum-based cancer chemotherapy10.1038/nrc2167 ↗
2. The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs10.1021/acs.chemrev.5b00597 ↗
3. Bioorganometallic chemistry-from teaching paradigms to medicinal applications10.1039/B707077M ↗
4. Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates10.1016/j.jinorgbio.2011.09.030 ↗
5. Novel and versatile imine-N-heterocyclic carbene half-sandwich iridium(III) complexes as lysosome-targeted anticancer agents10.1021/acs.inorgchem.8b01656 ↗
6. 100 years of metal coordination chemistry: from Alfred Werner to anticancer metallodrugs10.1515/pac-2014-0504 ↗
7. Organoiridium complexes: anticancer agents and catalysts10.1021/ar400266c ↗
8. Organometallic half-sandwich iridium anticancer complexes10.1021/jm2000932 ↗
9. Cisplatin in cancer therapy: molecular mechanisms of action10.1016/j.ejphar.2014.07.025 ↗
10. Cisplatin as an Anti-Tumor Drug: cellular mechanisms of activity, drug resistance and induced side effects10.3390/cancers3011351 ↗
11. Molecular mechanisms of resistance and toxicity associated with platinating agents10.1016/j.ctrv.2006.09.006 ↗
12. Preclinical perspectives on platinum resistance10.2165/00003495-200059004-00001 ↗
13. Potent half-sandwich iridium(III) and ruthenium(II) anticancer complexes containing a P^O-chelated ligand10.1021/acs.organomet.8b00402 ↗
14. organoiridium(III) anticancer complexes with C^N-chelated ligands10.1016/j.jinorgbio.2018.11.007 ↗
15. Contrasting reactivity and cancer cell cytotoxicity of isoelectronic organometallic iridium(III) complexes10.1021/ic200607j ↗
16. Lysosome-targeted phosphine-imine half-sandwich iridium(III) anticancer complexes: synthesis, characterization, and biological activity10.1021/acs.organomet.9b00080 ↗
17. Phosphorescent biscyclometallated iridium(III) ethylenediamine complexes functionalised with polar ester or carboxylate groups as bioimaging and visualisation reagents10.1039/C4DT02890B ↗
18. Group 9 organometallic compounds for therapeutic and bioanalytical applications10.1021/ar500310z ↗
19. A convenient approach to synthesize o-carborane-functionalized phosphorescent iridium(III) complexes for endocellular hypoxia imaging10.1002/chem.201603340 ↗
20. The cellular uptake and localization of non-emissive iridium(III) complexes as cellular reaction-based luminescence probes10.1016/j.biomaterials.2012.09.014 ↗
21. Lighting the way to see inside the live cell with luminescent transition metal complexes10.1016/j.ccr.2012.03.018 ↗
22. Iridium(III) complexes as therapeutic and bioimaging reagents for cellular applications10.1039/c2ra20967e ↗
23. Anticancer activity of complexes of the third row transition metals, rhenium, osmium, and iridium10.1039/C8DT01858H ↗
24. The development of anticancer ruthenium(II) complexes: from single molecule compounds to nanomaterials10.1039/C7CS00195A ↗
25. Lysosome-targeted cyclometalated iridium (III) anticancer complexes bearing phosphine-sulfonate ligands10.1002/aoc.4746 ↗
26. Dual-functional cyclometalated iridium imine NHC complexes: highly potent anticancer and antimetastatic agents10.1039/C8QI00920A ↗
27. Endoplasmic reticulum-localized iridium(III) complexes as efficient photodynamic therapy agents via protein modifications10.1021/jacs.6b05302 ↗
28. Cyclometalated iridium(III)–β-carboline complexes as potent autophagy-inducing agents10.1039/c4cc01461h ↗
29. Cyclometalated iridium(III) complexes as lysosome-targeted photodynamic anticancer and real-time tracking agents10.1039/C5SC01955A ↗
30. Highly potent extranuclear-targeted luminescent iridium(III) antitumor agents containing benzimidazole-based ligands with a handle for functionalization10.1039/C6CC07909A ↗
31. Iridium(III) complexes with five-membered heterocyclic ligands for combined photodynamic therapy and photoactivated chemotherapy10.1039/C7DT02477K ↗
32. Investigating intracellular localisation and cytotoxicity trends for neutral and cationic iridium tetrazolato complexes in live cells10.1002/chem.201701352 ↗
33. Rational design of NIR-emitting iridium(III) complexes for multimodal phosphorescence imaging of mitochondria under two-photon excitation10.1039/C7CC05193J ↗
34. Oncosis-inducing cyclometalated iridium(III) complexes10.1039/C8SC01142G ↗
35. Cyclometalated iridium(III) complexes as two-photon phosphorescent probes for specific mitochondrial dynamics tracking in living cells10.1002/chem.201501882 ↗
36. Electronic effects on reactivity and anticancer activity by half-sandwich N,N-chelated iridium(III) complexes10.1039/C8NJ03360A ↗
37. Inhibition of the Ras/Raf interaction and repression of renal cancer xenografts in vivo by an enantiomeric iridium(III) metal-based compound10.1039/C7SC00311K ↗
38. Zwitterionic and cationic half-sandwich iridium(III) ruthenium(II) complexes bearing sulfonate groups: synthesis, characterization and their different biological activities10.1039/C9DT00259F ↗
39. Light-up mitophagy in live cells with dual-functional theranostic phosphorescent iridium(III) complexes10.1021/acsami.7b01735 ↗
40. Phosphorescence imaging of living cells with amino acid-functionalized tris(2-phenylpyridine) iridium(III) complexes10.1021/ic201860s ↗
41. Zwitterionic iridium complexes: synthesis, luminescent properties, and their application in cell imaging10.1021/ic9021239 ↗
42. Dual emission from an ortho-metalated iridium(III) complex10.1021/ja00239a060 ↗
43. Synthesis and reactivity of water-soluble platinum(II) complexes containing nitrogen ligands10.1016/S0022-328X(03)00540-0 ↗
44. The fluorine effect in zwitterionic half-sandwich iridium(III) anticancer complexes10.1021/acs.inorgchem.9b03006 ↗
45. Optoelectronic properties of green and yellow light-emitting electrochemical cells based on cationic iridium complexes10.1016/j.poly.2013.04.029 ↗
46. Fluorescent half-sandwich phosphine-sulfonate iridium(III) and ruthenium(II) complexes as potential lysosome-targeted anticancer agents10.1016/j.dyepig.2018.11.009 ↗
47. Light-Up Mitophagy in live cells with dual-functional theranostic phosphorescent iridium(III) complexes10.1021/acsami.7b01735 ↗
48. Serendipitous synthesis of five-coordinated half-sandwich aminoimine iridium(III) and ruthenium(II) complexes and their application as potent anticancer agents10.1021/acs.inorgchem.9b00282 ↗
49. The potent oxidant anticancer activity of organoiridium catalysts10.1002/anie.201311161 ↗
50. Series of new cationic iridium(III) complexes with tunable emission wavelength and excited state properties: structures, theoretical calculations, and photophysical and electrochemical properties10.1021/ic052034j ↗
51. Synthesis and photophysical, electrochemical, and electrophosphorescent properties of a series of iridium(III) complexes based on quinoline derivatives and different β-diketonate ligands10.1021/om060037d ↗
52. Highly phosphorescent bis-cyclometalated iridium complexes: synthesis, photophysical characterization, and use in organic light emitting diodes10.1021/ja003693s ↗
53. Blue and near-UV phosphorescence from iridium complexes with cyclometalated pyrazolyl or N-heterocyclic carbene ligands10.1021/ic051296i ↗
54. Synthesis and characterization of phosphorescent cyclometalated iridium complexes10.1021/ic0008969 ↗
55. Cyclometalated iridium(III) N-heterocyclic carbene complexes as potential mitochondrial anticancer and photodynamic agents10.1039/C7DT01903C ↗
56. Novel lysosome-targeted cyclometalated Iridium(III) anticancer complexes containing imine-N-heterocyclic carbene ligands: synthesis, spectroscopic properties and biological activity10.1016/j.dyepig.2018.09.044 ↗
57. Significant effects of counteranions on the anticancer activity of iridium(III) complexes10.1039/C8CC01326H ↗
58. Imine-N-heterocyclic carbenes as versatile ligands in ruthenium(II) p-cymene anticancer complexes: a structure-activity relationship study10.1002/asia.201801058 ↗
59. Half-sandwich iridium and ruthenium complexes: effective tracking in cells and anticancer studies10.1021/acs.inorgchem.8b02161 ↗
60. Smart “on-off-on” fluorescent switches for drug visual loading and responsive delivery10.1016/j.dyepig.2019.107893 ↗
61. Lysosomal membrane permeabilization in cell death10.1038/onc.2008.310 ↗